Loading organizations...
Loading organizations...
Bot M.D. is a technology company.
Bot MD builds an AI-powered patient engagement platform that deploys specialized AI agents for hospitals and clinics. These intelligent agents automate various patient interactions, including instant responses to inquiries, appointment scheduling, pre-admission processes, remote monitoring, and patient education. The platform seamlessly integrates with existing hospital systems, leveraging a proprietary retrieval-augmented generation (RAG) and large language model (LLM) to handle diverse workflows and provide personalized, round-the-clock automation.
The company was founded in 2018 by Dorothea Koh and Yanchuan Sim. Koh, a Stanford Biodesign Fellowship alumna from 2008, brought significant insight into healthcare system challenges. Their foundational vision stemmed from recognizing the immense administrative load on medical professionals and the potential for artificial intelligence to empower doctors, enabling them to dedicate more time to critical patient care by automating routine yet essential tasks.
Bot MD’s platform serves hospitals and clinics worldwide, aiming to enhance the productivity of care teams and significantly reduce manual workload. The company’s mission centers on streamlining the entire patient journey, from initial contact to post-care, ensuring inclusive, consistent, and scalable patient engagement. Bot MD envisions a future where healthcare providers can focus predominantly on clinical care, supported by intelligent automation that drives operational efficiency and improves overall patient outcomes.
Bot M.D. has raised $5.0M across 1 funding round.
Bot M.D. has raised $5.0M in total across 1 funding round.
Bot M.D. (also stylized as Bot MD) is a Y Combinator-backed technology company building AI-powered platforms for healthcare providers, primarily hospitals and clinics. Its core products automate patient engagement—including enquiries, appointment scheduling, marketing, and monitoring—while providing doctors with instant access to clinical information, boosting revenue by 20–30% and scaling care in underserved markets.[1][4] Serving over 20,000 doctors and 100,000+ patients globally, especially in Southeast Asia, Bot MD addresses clinician workload and access gaps through proprietary AI agents that integrate with EMR systems, popular chat apps, and hospital protocols.[1][2][3]
The platform solves key problems like manual scheduling, no-show rates, and fragmented clinical data by offering 24/7 multilingual AI that mirrors efficient workflows, automates intake/feedback, and powers omnichannel interactions. Growth momentum includes a $5M Series A in 2021 led by Monk's Hill Ventures, expansion from doctor tools to enterprise patient platforms post-COVID, and partnerships with major providers like Parkway Radiology and St. Luke's Medical Center.[1][3][4]
Bot MD originated as a weekend hobby project in 2018 by co-founders Dot (CEO) and Yanchuan (CTO), who prototyped it over nights at a Coffee Bean cafe in downtown Singapore.[1] Dot, passionate about scaling healthcare in emerging markets like China, India, and Indonesia after years in those regions, identified the need to disseminate urban-concentrated medical knowledge to rural areas and support better clinical decisions.[5] The duo joined Y Combinator's summer 2018 batch, moving to a Palo Alto garage, then returned to Singapore post-program.[1]
Early traction came quickly: version 1 launched in July 2018, reaching 13,000+ doctors worldwide within a year.[5] A pivotal moment was the 2020 COVID-19 response, launching Bot MD Care to monitor migrant workers' vitals via chat apps, evolving into a full patient engagement platform for large hospitals.[1] Today, headquartered in Anaheim, California, with operations in Singapore, San Francisco, Manila, and Bangkok, the company has raised $5M total funding and grown to 27 employees.[2]
Bot MD stands out in AI healthcare through clinician-centric design and deep customization:
Bot MD rides the AI agent wave in healthcare, capitalizing on post-pandemic demand for automation amid clinician shortages and rising patient volumes in emerging markets like Southeast Asia, where urban-rural knowledge gaps persist.[1][5] Timing aligns with LLM advancements and chat app dominance (e.g., WhatsApp), enabling seamless scaling without heavy infrastructure; market forces like telemedicine growth and revenue pressures on hospitals favor its 20–30% uplift claims.[4]
It influences the ecosystem by partnering with institutions (e.g., Stanford pilots, large chains), standardizing AI for clinical workflows, and amplifying doctor efficiency—potentially accelerating care equity in high-growth regions like Indonesia, Philippines, and India.[1][3][5]
Bot MD is poised for expansion as AI agents mature, targeting deeper US/EU penetration beyond Asia while enhancing predictive features like no-show prevention and personalized care paths. Trends like multimodal AI (voice/video) and regulatory tailwinds for secure health tech will shape its trajectory, potentially driving acquisitions by telehealth giants. Its doctor-first evolution from hobby to 20,000+ user platform underscores enduring potential to scale quality care globally, fulfilling its founding mission to empower clinicians at the heart of patient impact.[1][3]
Bot M.D. has raised $5.0M in total across 1 funding round.
Bot M.D.'s investors include Jean-Luc Butel, Lu Yoh-Chie, Steve Blank, SeaX Ventures, Jui Lim, XA Network.
Bot M.D. has raised $5.0M across 1 funding round. Most recently, it raised $5.0M Bot MD - Series A in February 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 2, 2021 | $5.0M Bot MD - Series A | Jean-Luc Butel, Lu Yoh-Chie, Steve Blank, SeaX Ventures, Jui Lim, XA Network |